Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) rose 18.6% on Thursday . The company traded as high as $34.92 and last traded at $31.10. Approximately 514,390 shares changed hands during trading, an increase of 529% from the average daily volume of 81,766 shares. The stock had previously closed at $26.23.
KALV has been the topic of a number of research analyst reports. TheStreet raised shares of Kalvista Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Thursday, December 20th. BidaskClub upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, January 4th. Cantor Fitzgerald reiterated a “buy” rating and set a $32.00 price objective on shares of Kalvista Pharmaceuticals in a report on Friday, December 14th. ValuEngine upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Finally, Zacks Investment Research upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $26.00 price objective on the stock in a report on Saturday, March 2nd. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $27.00.
The firm has a market capitalization of $411.35 million, a price-to-earnings ratio of -20.33 and a beta of 2.45.
In related news, major shareholder Svlsf Iv, Llc sold 43,378 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $22.91, for a total value of $993,789.98. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Life Sciences Fund Iv (Gp) Sv sold 214,198 shares of the company’s stock in a transaction dated Thursday, February 21st. The stock was sold at an average price of $20.55, for a total transaction of $4,401,768.90. The disclosure for this sale can be found here. Insiders sold a total of 314,718 shares of company stock worth $6,509,410 in the last 90 days. 38.40% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Flinton Capital Management LLC acquired a new stake in shares of Kalvista Pharmaceuticals in the 4th quarter worth about $26,000. Ramsey Quantitative Systems bought a new position in shares of Kalvista Pharmaceuticals during the 4th quarter valued at approximately $35,000. Bank of Montreal Can bought a new position in shares of Kalvista Pharmaceuticals during the 4th quarter valued at approximately $90,000. Virtu Financial LLC bought a new position in shares of Kalvista Pharmaceuticals during the 3rd quarter valued at approximately $216,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Kalvista Pharmaceuticals during the 3rd quarter valued at approximately $274,000. Institutional investors own 77.31% of the company’s stock.
Kalvista Pharmaceuticals Company Profile (NASDAQ:KALV)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Featured Story: Relative Strength Index
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.